View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMETabolic EXplorer 配当と自社株買い配当金 基準チェック /06METabolic EXplorer配当金を支払った記録がありません。主要情報n/a配当利回り-129.9%バイバック利回り総株主利回り-129.9%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares IndexNew Risk • Sep 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Revenue has declined by 36% over the past year. Market cap is less than US$10m (€6.16m market cap, or US$6.87m).New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).分析記事 • Feb 10METabolic EXplorer S.A. (EPA:METEX) Surges 28% Yet Its Low P/S Is No Reason For ExcitementThose holding METabolic EXplorer S.A. ( EPA:METEX ) shares would be relieved that the share price has rebounded 28% in...分析記事 • Dec 18Why Investors Shouldn't Be Surprised By METabolic EXplorer S.A.'s (EPA:METEX) 27% Share Price PlungeTo the annoyance of some shareholders, METabolic EXplorer S.A. ( EPA:METEX ) shares are down a considerable 27% in the...New Risk • Oct 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.7m market cap, or US$12.4m).Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings.分析記事 • Oct 01Health Check: How Prudently Does METabolic EXplorer (EPA:METEX) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$26.8m).分析記事 • Jul 30News Flash: One METabolic EXplorer S.A. (EPA:METEX) Analyst Has Been Trimming Their Revenue ForecastsThe latest analyst coverage could presage a bad day for METabolic EXplorer S.A. ( EPA:METEX ), with the covering...Major Estimate Revision • Jul 29Consensus revenue estimates decrease by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €235.0m to €200.0m. EPS estimate unchanged from -€0.44 per share at last update. Chemicals industry in France expected to see average net income growth of 3.5% next year. Consensus price target of €1.20 unchanged from last update. Share price fell 13% to €0.97 over the past week.Major Estimate Revision • Jun 14Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -€0.40 to -€0.35 per share. Revenue forecast unchanged from €235.0m at last update. Chemicals industry in France expected to see average net income growth of 7.6% next year. Consensus price target of €1.20 unchanged from last update. Share price rose 5.1% to €1.07 over the past week.Major Estimate Revision • Jan 06Consensus EPS estimates fall by 133%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €242.1m to €232.7m. Losses expected to increase from €0.39 per share to €0.91. Chemicals industry in France expected to see average net income growth of 22% next year. Consensus price target down from €1.85 to €1.60. Share price rose 6.0% to €1.28 over the past week.Price Target Changed • Nov 16Price target decreased to €1.85Down from €2.70, the current price target is provided by 1 analyst. New target price is 14% above last closing price of €1.62. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.39 compared to earnings per share of €2.31 last year.Major Estimate Revision • Oct 07Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €290.6m to €264.3m. Losses expected to increase from €0.30 per share to €0.38. Chemicals industry in France expected to see average net income growth of 19% next year. Consensus price target down from €2.70 to €1.94. Share price fell 4.4% to €1.51 over the past week.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Chemicals industry in France.Major Estimate Revision • Sep 22Consensus EPS estimates fall by 15%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €298.3m to €290.6m. Losses expected to increase from €0.26 per share to €0.30. Chemicals industry in France expected to see average net income growth of 0.1% next year. Consensus price target of €2.70 unchanged from last update. Share price fell 19% to €1.67 over the past week.分析記事 • Jul 10Downgrade: The Latest Revenue And EPS Forecasts For METabolic EXplorer S.A. (EPA:METEX)Market forces rained on the parade of METabolic EXplorer S.A. ( EPA:METEX ) shareholders today, when the covering...Major Estimate Revision • Jul 09Consensus revenue estimates fall by 16%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €355.8m to €298.3m. Forecast loss of -€0.26, down from profit of €0.30 per share profit previously. Chemicals industry in France expected to see average net income growth of 0.8% next year. Consensus price target down from €10.50 to €2.85. Share price fell 10% to €1.79 over the past week.分析記事 • Jun 14Does METabolic EXplorer (EPA:METEX) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • May 10Is METabolic EXplorer S.A. (EPA:METEX) Potentially Undervalued?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a double-digit share price rise of...Price Target Changed • Apr 27Price target increased to €10.50Up from €7.80, the current price target is provided by 1 analyst. New target price is 92% above last closing price of €5.48. Stock is up 5.7% over the past year.Reported Earnings • Apr 02Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 107%, compared to a 13% growth forecast for the industry in France.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.05, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Chemicals industry in France. Total returns to shareholders of 189% over the past three years.分析記事 • Jan 25What Is METabolic EXplorer S.A.'s (EPA:METEX) Share Price Doing?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a decent share price growth in the...Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to €6.16, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 19x in the Chemicals industry in France. Total returns to shareholders of 258% over the past three years.分析記事 • Oct 06Statutory Earnings May Not Be The Best Way To Understand METabolic EXplorer's (EPA:METEX) True PositionWe didn't see METabolic EXplorer S.A.'s ( EPA:METEX ) stock surge when it reported robust earnings recently. We decided...分析記事 • May 12METabolic EXplorer (EPA:METEX) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).分析記事 • Mar 18The METabolic EXplorer (EPA:METEX) Share Price Has Soared 428%, Delighting Many ShareholdersWhile some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...Is New 90 Day High Low • Mar 02New 90-day high: €4.82The company is up 118% from its price of €2.21 on 01 December 2020. The French market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 8.0% over the same period.Is New 90 Day High Low • Feb 09New 90-day high: €3.13The company is up 84% from its price of €1.70 on 10 November 2020. The French market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Jan 23New 90-day high: €2.95The company is up 68% from its price of €1.76 on 23 October 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.Is New 90 Day High Low • Jan 05New 90-day high: €2.87The company is up 71% from its price of €1.68 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Dec 04New 90-day high: €2.58The company is up 41% from its price of €1.83 on 04 September 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.分析記事 • Dec 03Investors Who Bought METabolic EXplorer (EPA:METEX) Shares A Year Ago Are Now Up 74%The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...Is New 90 Day High Low • Nov 19New 90-day high: €1.89The company is up 5.0% from its price of €1.80 on 20 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 14New 90-day low: €1.62The company is down 16% from its price of €1.92 on 16 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 1.0% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.決済の安定と成長配当データの取得安定した配当: METEXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: METEXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場METabolic EXplorer 配当利回り対市場METEX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (METEX)n/a市場下位25% (FR)2.0%市場トップ25% (FR)5.6%業界平均 (Chemicals)2.2%アナリスト予想 (METEX) (最長3年)n/a注目すべき配当: METEXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: METEXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: METEXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: METEXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YFR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/09 03:47終値2024/10/09 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋METabolic EXplorer S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Arsene GuekamCIC Market Solutions (ESN)Nicolas RoyotPortzamparc BNP ParibasChristophe Dombu YoutaPortzamparc BNP Paribas
お知らせ • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares Index
New Risk • Sep 29New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Revenue has declined by 36% over the past year. Market cap is less than US$10m (€6.16m market cap, or US$6.87m).
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).
分析記事 • Feb 10METabolic EXplorer S.A. (EPA:METEX) Surges 28% Yet Its Low P/S Is No Reason For ExcitementThose holding METabolic EXplorer S.A. ( EPA:METEX ) shares would be relieved that the share price has rebounded 28% in...
分析記事 • Dec 18Why Investors Shouldn't Be Surprised By METabolic EXplorer S.A.'s (EPA:METEX) 27% Share Price PlungeTo the annoyance of some shareholders, METabolic EXplorer S.A. ( EPA:METEX ) shares are down a considerable 27% in the...
New Risk • Oct 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.7m market cap, or US$12.4m).
Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings.
分析記事 • Oct 01Health Check: How Prudently Does METabolic EXplorer (EPA:METEX) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$26.8m).
分析記事 • Jul 30News Flash: One METabolic EXplorer S.A. (EPA:METEX) Analyst Has Been Trimming Their Revenue ForecastsThe latest analyst coverage could presage a bad day for METabolic EXplorer S.A. ( EPA:METEX ), with the covering...
Major Estimate Revision • Jul 29Consensus revenue estimates decrease by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €235.0m to €200.0m. EPS estimate unchanged from -€0.44 per share at last update. Chemicals industry in France expected to see average net income growth of 3.5% next year. Consensus price target of €1.20 unchanged from last update. Share price fell 13% to €0.97 over the past week.
Major Estimate Revision • Jun 14Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -€0.40 to -€0.35 per share. Revenue forecast unchanged from €235.0m at last update. Chemicals industry in France expected to see average net income growth of 7.6% next year. Consensus price target of €1.20 unchanged from last update. Share price rose 5.1% to €1.07 over the past week.
Major Estimate Revision • Jan 06Consensus EPS estimates fall by 133%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €242.1m to €232.7m. Losses expected to increase from €0.39 per share to €0.91. Chemicals industry in France expected to see average net income growth of 22% next year. Consensus price target down from €1.85 to €1.60. Share price rose 6.0% to €1.28 over the past week.
Price Target Changed • Nov 16Price target decreased to €1.85Down from €2.70, the current price target is provided by 1 analyst. New target price is 14% above last closing price of €1.62. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.39 compared to earnings per share of €2.31 last year.
Major Estimate Revision • Oct 07Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €290.6m to €264.3m. Losses expected to increase from €0.30 per share to €0.38. Chemicals industry in France expected to see average net income growth of 19% next year. Consensus price target down from €2.70 to €1.94. Share price fell 4.4% to €1.51 over the past week.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Chemicals industry in France.
Major Estimate Revision • Sep 22Consensus EPS estimates fall by 15%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €298.3m to €290.6m. Losses expected to increase from €0.26 per share to €0.30. Chemicals industry in France expected to see average net income growth of 0.1% next year. Consensus price target of €2.70 unchanged from last update. Share price fell 19% to €1.67 over the past week.
分析記事 • Jul 10Downgrade: The Latest Revenue And EPS Forecasts For METabolic EXplorer S.A. (EPA:METEX)Market forces rained on the parade of METabolic EXplorer S.A. ( EPA:METEX ) shareholders today, when the covering...
Major Estimate Revision • Jul 09Consensus revenue estimates fall by 16%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €355.8m to €298.3m. Forecast loss of -€0.26, down from profit of €0.30 per share profit previously. Chemicals industry in France expected to see average net income growth of 0.8% next year. Consensus price target down from €10.50 to €2.85. Share price fell 10% to €1.79 over the past week.
分析記事 • Jun 14Does METabolic EXplorer (EPA:METEX) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
分析記事 • May 10Is METabolic EXplorer S.A. (EPA:METEX) Potentially Undervalued?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a double-digit share price rise of...
Price Target Changed • Apr 27Price target increased to €10.50Up from €7.80, the current price target is provided by 1 analyst. New target price is 92% above last closing price of €5.48. Stock is up 5.7% over the past year.
Reported Earnings • Apr 02Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 107%, compared to a 13% growth forecast for the industry in France.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.05, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 20x in the Chemicals industry in France. Total returns to shareholders of 189% over the past three years.
分析記事 • Jan 25What Is METabolic EXplorer S.A.'s (EPA:METEX) Share Price Doing?METabolic EXplorer S.A. ( EPA:METEX ), might not be a large cap stock, but it saw a decent share price growth in the...
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to €6.16, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 19x in the Chemicals industry in France. Total returns to shareholders of 258% over the past three years.
分析記事 • Oct 06Statutory Earnings May Not Be The Best Way To Understand METabolic EXplorer's (EPA:METEX) True PositionWe didn't see METabolic EXplorer S.A.'s ( EPA:METEX ) stock surge when it reported robust earnings recently. We decided...
分析記事 • May 12METabolic EXplorer (EPA:METEX) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).
分析記事 • Mar 18The METabolic EXplorer (EPA:METEX) Share Price Has Soared 428%, Delighting Many ShareholdersWhile some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
Is New 90 Day High Low • Mar 02New 90-day high: €4.82The company is up 118% from its price of €2.21 on 01 December 2020. The French market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Feb 09New 90-day high: €3.13The company is up 84% from its price of €1.70 on 10 November 2020. The French market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Jan 23New 90-day high: €2.95The company is up 68% from its price of €1.76 on 23 October 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: €2.87The company is up 71% from its price of €1.68 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Dec 04New 90-day high: €2.58The company is up 41% from its price of €1.83 on 04 September 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.
分析記事 • Dec 03Investors Who Bought METabolic EXplorer (EPA:METEX) Shares A Year Ago Are Now Up 74%The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
Is New 90 Day High Low • Nov 19New 90-day high: €1.89The company is up 5.0% from its price of €1.80 on 20 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 14New 90-day low: €1.62The company is down 16% from its price of €1.92 on 16 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 1.0% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €8.44m, with losses narrowing by 5.4% from the prior year.